Xenon Pharmaceuticals Inc (STU:XP0)
€ 38.4 -0.2 (-0.52%) Market Cap: 2.90 Bil Enterprise Value: 2.27 Bil PE Ratio: 0 PB Ratio: 3.56 GF Score: 47/100

Xenon Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript

May 16, 2023 / 07:05PM GMT
Release Date Price: €37.6 (+3.30%)
Brian Abrahams
RBC Capital Markets - Moderator

All right. Good afternoon, everyone. Brian Abrahams, one of the senior biotech analysts here at RBC Capital Markets. Our next featured company is Xenon Pharmaceuticals represented by their CEO, Ian Mortimer; and their CFO, Sherry Aulin. So thanks so much for joining us.

Questions & Answers

Brian Abrahams
RBC Capital Markets - Moderator

Lots to talk about. And a lot of progress continues to be made with 1101. I want to maybe start with the bigger picture question on 1101. As you start to think about the opportunity for the drug post the successful Phase 2 X-TOLE data, I'm curious, the latest that you're hearing from your market research and from physicians for how 1101 can slot into that future treatment paradigm?

And maybe you could talk about the unmet need overall in epilepsy, in focal and generalized seizures. Just the numbers of patients, how plugged into treatment they are, where the failures are today, and where you're looking to focus the drug? And then we can go from there.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot